Recommended Scope for NPS Testing in the United States

NPS SCOPE **Q2 2025**

PURPOSE: The objective of this report is to provide updated guidance in developing an appropriate analytical scope of testing for novel psychoactive substances (NPS) in the United States (and around the world) based on current trends and intelligence. *This report is based on information available in Q1 2025 and early Q2 2025 and is subject to change along with the drug market.*

SUMMARY: The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation of NPS. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. **CFSRE**'s **NPS Discovery** and the **SOFT NPS Committee** have established the below recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national and international perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are listed for each NPS. These values are categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class.

BENZODIAZEPINES		OPIOIDS		STIMULANTS & HALLUCINOGENS		SYNTHETIC CANNABINOIDS		SEMI-SYNTHETIC CANNABINOIDS		MISCELLANEOUS	
TIER ONE (STRONGLY RECOMMEND)											
Bromazolam	1-10	Metonitazene	<1	*N,N*-Dimethylpentylone	>10	MDMB-4en-PINACA	<1	Δ^8-THC	1-10	Medetomidine	1-10
Desalkylgidazepam†	1-10	Protonitazene	<1	*N*-Isopropyl Butylone	>10	5F-MDMB-PINACA (5F-ADB)	<1	Δ^8-THC-COOH	1-10	Xylazine	1-10
Flubromazepam	1-10	Carfentanil	<1	▪alpha-PiHpP / alpha-PHpP	>10	ADB-BINACA (-BUTINACA)	<1	9(R)-HHC / 9(S)-HHC	1-10	Mitragynine	1-10
Phenazolam	1-10	*o/m/p*-Fluorofentanyl	1-10	2F-2oxo-PCE / Fluorexetamine	>10	ADB-4en-PINACA	<1	9(R)-HHC-COOH / 9(S)-HHC-COOH	1-10	7OH-Mitragynine	1-10
8-Aminoclonazolam‡	1-10	*o/m/p*-Methylfentanyl	1-10	2/3/4-Methylmethcathinone	>10	MDMB-BINACA (-BUTINACA)	<1	-	-	-	-
TIER TWO (RECOMMEND)											
Clonazolam‡	<1	*N*-Pyrrolidino Protonitazene	<1	▾Pentylone	>10	MDMB-PICA	<1	Δ^{10}-THC	1-10	Tianeptine	>10
Flualprazolam	1-10	▪*N*-Pyrrolidino Isotonitazene	<1	2/3/4-Chloromethcathinone	>10	▪ADB-CHMINACA	<1	Δ^{10}-THC-COOH	1-10	Dextro/Levo Methorphan	>10
Etizolam†	1-10	*N*-Pyrrolidino Etonitazene	<1	alpha-PiHP / alpha-PHP	>10	▪4CN-CUMYL-BINACA (-BUTINACA)	<1	THC-O-Acetate	1-10	Etomidate	1-10
Flubromazolam	1-10	*N*-Desethyl Isotonitazene	<1	MDPHP / MDPiHP	>10	5F-MDMB-PICA	<1	HHC-O-Acetate	1-10	-	-
TIER THREE (CONSIDER)											
Desalkylflurazepam†	1-10	*N*-Desethyl Etonitazene	<1	2C-B	<1	4F-MDMB-BICA	<1	THCP	1-10	BTMPS	1-10
▪Phenazepam†	1-10	*N*-Pyrrolidino Metonitazene	<1	*N*-Cyclohexyl Methylone	>10	▾4F-MDMB-BINACA	<1	HHCP	1-10	▪*TMF-Related Substances**	>10
Pyrazolam	1-10	*N*-Desethyl Protonitazene	<1	Eutylone	>10	▪MDMB-INACA	<1	CBDP	1-10	Phenibut	>10
▪Ethylbromazolam	1-10	▪*N*-Desethyl Metonitazene	<1	▪2F-MBZP / 4F-MBZP	>10	▪ADB-INACA	<1	HHCH	1-10	▪Kavain & Kavalactones	>10

Note: This may not be an all-inclusive list. Laboratories should consider additional NPS for inclusion (or exclusion) based on local, national, and/or international trends.

**Tetramethylfentanyl (TMF)-Related Substances*

cfsre | NPS DISCOVERY

Acknowledgements: These scope recommendations were developed by the Society of Forensic Toxicologists (SOFT) NPS Committee in collaboration with the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. This report was prepared by Alex Krotulski, Kayla Ellefsen, Donna Papsun, Elisa Shoff, Svante Vikingsson, Michael Truver, Celia Modell, Lana Goodson, Sandrine Mérette, Amy Patton, Helen Chang, Jillian Neifeld, and Barry Logan. The authors would like to acknowledge scientists and staff at our laboratories for their related involvements and contributions.

Disclaimer: The recommendations in this report are subject to change with time as new information becomes available. †Toxicologists should consider that NPS may appear due to varying pharmaceutical origins.

Funding: CFSRE's NPS Discovery is funded in-part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 15PNIJ-24-GK-00981-COAP, "Novel Psychoactive Substance Discovery, Education, and Reporting Institute [NPS DiscERNi]"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.

Suggested Citation: Krotulski et al. (2025) *Recommended Scope for NPS Testing in the United States Q2 2025*, Center for Forensic Science Research and Education, United States.

Recommended Scope for NPS Testing in the United States

NPS SCOPE **Q2 2025**

PROVIDE FEEDBACK: If you are interested in providing feedback to the SOFT NPS Committee and CFSRE's NPS Discovery program on specific drugs and/or drug classes, the content and formatting of our latest scope recommendations, topics related to NPS and/or NPS testing, or any other items of interest, please email us at npsdiscovery@cfsre.org.

RECOMMENDED NPS METABOLITES: Our recommendations now encompass metabolites of specified NPS to consider in testing scopes, when known or postulated with high certainty based on literature or prior drug similarity. Laboratories should note the following: NPS metabolize to more than one metabolite. Determining the primary metabolite can be difficult and variable based on a variety of factors. NPS metabolites are found at varying abundances in different matrices. This is not intended to be an exhaustive list. Some metabolites listed may be predictive.

RECOMMENDED METABOLITES FOR SPECIFIC NPS				
Bromazolam ▸ alpha-Hydroxy Bromazolam	Metonitazene ▸ *N*-Desethyl Metonitazene & 5-Aminometonitazene	*N,N*-Dimethylpentylone ▸ Pentylone	MDMB-4en-PINACA ▸ MDMB-4en-PINACA 3,3-Dimethylbutanoic Acid	Δ^8-THC ▸ Δ^8-THC-COOH
Desalkylgidazepam ▸ 3-Hydroxy Desalkylgidazepam	Protonitazene ▸ *N*-Desethyl Protonitazene & 5-Aminoprotonitazene	*N*-Isopropyl Butylone ▸ *N*-Desalkyl Butylone	5F-MDMB-PINACA (5F-ADB) ▸ 5F-MDMB-PINACA 3,3-Dimethylbutanoic Acid	9(R)-HHC / 9(S)-HHC ▸ 9(R)-HHC-COOH / 9(S)-HHC-COOH
Flubromazepam ▸ 3-Hydroxy Flubromazepam	*N*-Pyrrolidino Protonitazene & *N*-Pyrrolidino Isotonitazene ▸ *N*-Pyrrolidino 4'-OH Nitazene	2F-2-oxo-PCE ▸ 2F-Deschloronorketamine	ADB-BINACA (-BUTINACA) ▸ ADB-BINACA *N*-Butanoic Acid & MDMB-BINACA 3,3-Dimethylbutanoic Acid	Δ^{10}-THC ▸ Δ^{10}-THC-COOH
Phenazolam ▸ alpha-Hydroxy Phenazolam	*N*-Desethyl Isotonitazene ▸ *N,N*-Didesethyl Isotonitazene & 5-Amino *N*-Desethyl Isotonitazene	2/3/4-Methylmethcathinone ▸ 2/3/4-Methylcathinone	ADB-4en-PINACA ▸ MDMB-4en-PINACA 3,3-Dimethylbutanoic Acid	Medetomidine ▸ 3-Hydroxy Medetomidine
Flualprazolam ▸ alpha-Hydroxy Flualprazolam	*N*-Pyrrolidino Etonitazene ▸ *N*-Pyrrolidino 4'-OH Nitazene	2/3/4-Chloromethcathinone ▸ 2/3/4-Chlorocathinone	MDMB-BINACA (-BUTINACA) ▸ MDMB-BINACA 3,3-Dimethylbutanoic Acid	Xylazine ▸ 3-Hydroxy Xylazine & 4-Hydroxy Xylazine
Clonazolam ▸ 8-Aminoclonazolam	*N*-Desethyl Isotonitazene ▸ *N,N*-Didesethyl Isotonitazene & 5-Amino *N*-Desethyl Isotonitazene	alpha-PiHP / alpha-PHP ▸ beta-Hydroxy-alpha-PiHP / beta-Hydroxy-alpha-PHP	ADB-CHMINACA ▸ MDMB-CHMINACA 3,3-Dimethylbutanoic Acid	Mitragynine ▸ 7-Hydroxy Mitragynine & Pseudoindoxyl Mitragynine
Carfentanil ▸ Norcarfentanil	*o/m/p*-Fluorofentanyl ▸ *o/m/p*-Fluoronorfentanyl	*o/m/p*-Methylfentanyl ▸ *o/m/p*-Methylnorfentanyl	4CN-CUMYL-BINACA (-BUTINACA) ▸ 4CN-CUMYL-BINACA *N*-Butanoic Acid	Dextro/Levo Methorphan ▸ Dextrorphan or Levorphanol

cfsre | NPS DISCOVERY

Acknowledgements: These scope recommendations were developed by the Society of Forensic Toxicologists (SOFT) NPS Committee in collaboration with the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. This report was prepared by Alex Krotulski, Kayla Ellefsen, Donna Papsun, Elisa Shoff, Svante Vikingsson, Michael Truver, Celia Modell, Lana Goodson, Sandrine Mérette, Amy Patton, Helen Chang, Jillian Neifeld, and Barry Logan. The authors would like to acknowledge scientists and staff at our laboratories for their related involvements and contributions.

Disclaimer: The recommendations in this report are subject to change with time as new information becomes available. †Toxicologists should consider that NPS may appear due to varying pharmaceutical origins.

Funding: CFSRE's NPS Discovery is funded in-part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 15PNIJ-24-GK-00981-COAP, "Novel Psychoactive Substance Discovery, Education, and Reporting Institute [NPS DiscERn]"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.

Suggested Citation: Krotulski et al. (2025) *Recommended Scope for NPS Testing in the United States Q2 2025*, Center for Forensic Science Research and Education, United States.